For investors looking to join solid fundamental growth with positive technical patterns, a particular screening method can be useful. This process selects for stocks that show firm earnings momentum, as judged by a unique High Growth Momentum Rating, while also displaying good price trends and helpful chart patterns through Technical and Setup Quality Ratings. The aim is to find companies where notable fundamental improvement may be ready to push the next stage of a price increase from a state of technical health.
High Growth Momentum Fundamentals
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) offers a strong case for growth investors, scoring a 7 out of 10 on the High Growth Momentum Rating. This rating combines short-term earnings momentum, speed of change, and analyst opinion. Kiniksa’s score is supported by several notable fundamental measures:
- High Earnings Growth: The company's trailing twelve-month (TTM) EPS has increased by a notable 421% compared to the prior year. Recent quarterly performance is more pronounced, with EPS growth of 228% in the last quarter and 483% in the quarter before that.
- Firm and Increasing Revenue: Top-line growth is equally solid. TTM revenue is up 56% year-over-year, with recent quarterly sales growth regularly above 60%. This shows that earnings growth is backed by growing commercial operations.
- Cash Flow Generation: A key indicator of financial condition, Kiniksa's free cash flow per share has risen sharply, showing growth of nearly 4,000% over the past year. This gives the company important flexibility to fund its pipeline or give capital to shareholders.
- Positive Estimate Revisions: While the EPS growth story is firm, it is significant that analyst estimates for next year's revenue have been adjusted higher by 0.2% over the last three months, showing ongoing belief in the company's commercial path.
These elements are key to the high-growth momentum plan, which looks for companies not only growing, but where the speed of growth is increasing and exceeding forecasts, a situation that frequently comes before notable stock price change.
Technical Health and Setup Quality
A firm fundamental story is most effective when it matches a positive price trend. According to ChartMill's detailed technical report, Kiniksa performs well here too, receiving a complete Technical Rating of 10. This score shows outstanding relative performance and a maintained upward trend.
- Market Outperformance: The stock is doing better than 93% of the whole market over the past year and is in the top 20% of its biotechnology industry group.
- Set Upward Trend: All main moving averages (20, 50, 100, and 200-day) are increasing and arranged positively, with the stock trading above them. The long-term trend is labeled as positive.
- Pause Within a Trend: At present, the short-term trend is neutral, showing the stock is resting. This has led to a high Setup Quality Rating of 8. The analysis states "reduced volatility while prices have been consolidating in the most recent period," which often comes before a resumption of the main trend.
- Clear Risk Points: The technical report finds a defined support area between $42.55 and $43.06, made by a combination of trendlines and moving averages. This gives a reasonable zone for investors to handle risk, as a fall below this area would indicate the pause may become a larger decline.
For momentum investors, this technical picture is favorable: a stock in a notable long-term upward trend that is now resting from its gains in a stable way, preparing for a possible next upward move.
A Merging Opportunity
Kiniksa Pharmaceuticals shows a merging of the standards wanted by this joined screening plan. The company is in the middle of a deep fundamental shift, with earnings and cash flow growing as its commercial product, ARCALYST, builds acceptance. This high-growth momentum is happening alongside a stock chart that has already noted this progress, shown by its 119% rise over the past year, and is now forming a new base of support.
The plan's logic is apparent: fundamental momentum gives the energy, while a firm technical setup gives both a timely point of entry and a structure for risk control. Kiniksa's high scores in all three ratings indicate it matches this idea, appearing as a commercial-stage biotech with improving financials that is technically ready for its next step.
Interested in finding more stocks that match this high-growth momentum breakout model? You can run the screen yourself using the High Growth Momentum Breakout Setups Screen.
Disclaimer: This article is for information only and does not form investment advice, a suggestion, or an offer to buy or sell any security. The study is based on given data and unique ratings, which may change. Investing has risk, including the possible loss of principal. Always do your own research and think about talking with a qualified financial advisor before making any investment choices.
